期刊文献+

胫前黏液性水肿发生发展机制的研究进展 被引量:7

Advances in the mechanisms of initiation and progression of pretibial myxedema
原文传递
导出
摘要 在自身免疫性甲状腺疾病背景下,循环自身抗体与成纤维细胞上自身抗原结合,产生IL~16和活化后可调节的正常T细胞表达并可能分泌的因子,趋化吸引CD4+T淋巴细胞.浸润T细胞活化成纤维细胞,分泌IL-6、8和巨噬细胞趋化蛋白-1,吸引炎性细胞浸润,形成血管周围炎.自身抗体、细胞因子与浸润T细胞使成纤维细胞合成过多透明质酸,发生黏液性水肿.局部创伤、感染可能起触发作用.持续大量细胞因子和透明质酸刺激成纤维细胞增殖并分化为肌成纤维细胞,过度合成细胞外基质,真皮纤维化,皮肤硬化. In autoimmune thyroid diseases, circulating autoantibodies bind to autoantigens on dermal fibroblasts. IL-16 and RANTES (regulated on activation, normal T cell expressed and secreted) produced by the autoantibody-binding fibroblasts chemoattract CD4 + T lymphocytes to infiltrate nnto the dermis. The infiltrated CD4+ T cells interact with and activate the fibroblasts to produce interleukin (IL)-6, IL-8 and macrophage chemotactic protein (MCP)-1, which recruit more inflammatory leukocytes and result in perivasculitis. In these processes, large amounts of cytokines, autoantibodies, together with the interactions between T lymphocytes and fibroblasts lead to the accumulation of hyalumnan in dermis, which results in pretibial myxedema. Local trauma or infection may initiate the above immunological processes. Large amounts of cytokines and hyaluronan persistently stimulate the fibroblasts to propagate and differentiate into myofibroblasts, as well as to overproduce extracellular matrices, which together causes dermal fibrosis and cutaneous sclerosis.
出处 《国际皮肤性病学杂志》 2010年第3期155-158,共4页 International Journal of Dermatology and Venereology
关键词 黏液水肿 免疫 成纤维细胞 Myxedema Immunity Fibroblasts
  • 相关文献

参考文献28

  • 1Davies TF,Ando T,Lin RY,et al.Thyrotropin receptor-associated diseases:from adenomata to Graves disease.J Clin Invest,2005,115(8):1972-1983.
  • 2Drexhage HA.Are there more than antibodies to the thyroidstimulating hormone receptor that meet the eye in Graves' disease? Endocrinology,2006,147(1):9-12.
  • 3Daumerie C,Ludgate M,Costagliola S,et al.Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy.Eur J Endocrinol,2002,146(1):35-38.
  • 4Felton J,Derrick EK,Price ML.Successful combined surgical and octreotide treatment of severe pretibial myxdema reviewed after 9 years.Br J Dermatol,2003,148(4):825-826.
  • 5Metcalfe R,Jordan N,Watson P,et al.Demonstration of immunoglobulin G,A,and E autoantibodies to the human thyrotropin receptor using flow cytometry.J Clin Endocrinol Metab,2002,87(4):1754-1761.
  • 6Pritchard J,Horst N,Cruikshank W,et al.Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts.J Immunol,2002,168(2):942-950.
  • 7Pritchard J,Han R,Horst N,et al.Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.J Immunol,2003,170 (12):63486354.
  • 8Tsui S,Naik V,Hoa N,et al.Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors:a tale of two antigens implicated in Graves'disease.J Immunol,2008,181(6):4397-4405.
  • 9Hwang CJ,Afifiyan N,Sand D,et al.Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40:CD154 hyperinduces IL-6,IL-8,and MCP-1.Invest Ophthalmol Vis Sci,2009,50(5):2262-2268.
  • 10Feldon SE,Park DJ,O'Loughlin CW,et al.Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.Invest Ophthalmol Vis Sci,2005,46(11):3913-3921.

同被引文献32

  • 1段炼,李险峰,陆克义,张承刚,胡光,刘建中,李思进.^(99)Tc^m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用[J].中华眼科杂志,2006(12):1068-1072. 被引量:18
  • 2刘燕强,辛天蓉,任自立.生长抑素及其受体[J].生理科学进展,2005,36(1):86-92. 被引量:19
  • 3弓健,吴秋莲,袁中满,谢金球,王丹,徐浩.放射性核素^(99m)Tc-奥曲肽体内生物分布的研究[J].暨南大学学报(自然科学与医学版),2006,27(6):825-829. 被引量:4
  • 4同济医科大学病理教研室,中国医科大学病理教研室.外科病理学[M].2版.武汉:湖北科学技术出版社,1999:216.
  • 5Fatourechi V,Myxedema P.Pathophysiology and treatment options[J].Am J Clin Dermatol,2005,6(5):295 -309.
  • 6Schwartz KM, Fatourechi V, Ahmed DD, et al. Dermopathy of Graves' disease (pretibial myxedema): long-term outcome[J]. J Clin Endocrinol Metab, 2002, 87(2): 438-446.
  • 7Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema[J]. Arch Dermatol, 1975, 111(2): 197-202.
  • 8Engin B,Munise Gtirniisel, Mustafa 0zdemir, et at. Successful combined pentoxifylline and intralesionaltriamcinolone acetonide treatment of severe pretibial myxedema [J]. Dermatol Online J, 2007, 13(2): 16.
  • 9Deng A, Song D. Muhipoint subcutaneous injection of long-act- ing glucocorticid as a cure for pretibial myxedema [J]. Thyroid, 2011,21(1): 83-85.
  • 10Lan C, Li C, Yang M, et al. Pretibial myxoedema with autoim- munity and hyperplasia treated with glueocorticoids and surgery [J]. Br J Dermatol, 2012, 166(2): 457-459.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部